High density lipoprotein,apolipoprotein A-1, and coronary artery disease |
| |
Authors: | Srivastava Rai Srivastava Neelam |
| |
Affiliation: | (1) Division of Atherosclerosis, Nutrition and Lipid Research, Department of Internal Medicine, Washington University School of Medicine, Saint Louis, Mo, USA;(2) Monsanto Company, Chesterfield Parkway, Mo, USA |
| |
Abstract: | High density lipoproteins (HDL), one of the main lipoprotein particles circulating in plasma, is involved in the reverse cholesterol transport. Several lines of evidence suggest that elevated levels of HDL is protective against coronary heart disease. The role of HDL in the removal of body cholesterol and in the regression of atherosclerosis add to the importance of understanding the molecular-cellular processes that determine plasma levels of HDL. Factors modulating plasma levels of HDL may have influence on the predisposition of an individual to premature coronary artery disease. Apolipoprotein (apo) A-I is the main apolipoprotein component of HDL and, to a large extent, sets the plasma levels of HDL. Thus, understanding the regulation of apoA-I gene expression may provide clues to raise plasma levels of HDL. This review discusses the various pathways that alter plasma levels of HDL. Since apoA-I is the main protein component of HDL and determines the plasma levels of HDL, this review also covers the regulation of apoA-I gene expression. |
| |
Keywords: | high density lipoprotein apolipoprotein A-I regulation coronary artery disease |
本文献已被 PubMed SpringerLink 等数据库收录! |
|